Bristol Myers Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing ...

This was the stock's fourth consecutive day of losses.

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Half of the patients treated with first-line biologic DMARDs achieved sustained, event-free remission compared with 12% of ...

Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS ...

High-yielding dividend stocks can be great investments to hold on to in your portfolio, but only if they're safe. Betting on ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Broad-based skin cancer screening may strain healthcare resources and lead to overdiagnosis, but it may also help catch more ...

Shares of Bristol Myers Squibb Co. BMY shed 3.32% to $55.30 Friday, on what proved to be an all-around grim trading session ...

Goldman Sachs downgraded Bristol Myers (BMY) to Neutral from Buy with a price target of $55, down from $67, after assuming coverage of the ...